Work

Abstract A4: Phase I clinical trial evaluating the safety, pharmacokinetics and biological effect of intravenous bevacizumab (avastin) in combination with escalating doses of AZD2171 (cediranib) administered orally for 21 consecutive days to patients with advanced malignancies (NCI protocol #7534)

Year: 2009

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-09-a4

Authors: David S. Hong, Darrin Davis, Aung Naing, Siqing Fu, Gerald Falchook, Linda W. Ricks, Nebe Bekele, David Mittleman, W. Liu, Percy Ivy, Roy Herbst, Razelle Kurzrock

Institutions: The University of Texas MD Anderson Cancer Center, National Institutes of Health, National Cancer Institute

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2312471499

Cites:

Cited by: 1

Related to: 10